mRNA science has shown the power of using an operating system framework for drug discovery and development with the successful COVID vaccine developments from Pfizer and Moderna. Integrating technology into the drug design process introduces unparalleled speed and flexibility. Kuano is using AI, quantum chemistry, and medical science to focus on enzyme reactions, a key factor in drug development, to develop novel therapeutics. The company is able to model enzyme reactions with unprecedented specificity allowing the drug makers to acquire the building blocks for pharmaceuticals that will address some of our most pressing and challenging diseases. London TechWatch caught up with Cofounder and CEO Vid Stojevic to learn more about how the Kuano changes the paradigm of drug development, the company’s strategic plans, and recent round of funding from ACF Investors, o2h Ventures, and a syndicate of Cambridge, London and UK-based angel investors.